跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2004-000443-17-LV
EUCTR2004-000443-17-LV进行中（未招募）不适用

A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Idenix Pharmaceuticals, Inc.0 个研究点目标入组 270 人开始时间: 2005年9月19日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
270
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Male or female, 16 to 70 years of age.
  • •2. Documented decompensated chronic hepatitis B defined by all of the following:
  • •Clinical history compatible with decompensated chronic hepatitis B related cirrhosis
  • •Child-Turcotte-Pugh score > 7 points.
  • •Evidence of hepatic cirrhosis or portal hypertension, documented by at least one of the following six methods:
  • •i. Evidence of cirrhosis by previous liver biopsy within 5 years prior to Screen,
  • •ii. Evidence of cirrhosis by liver biopsy prior to randomization,
  • •iii. Evidence of cirrhosis by ultrasound, CT, or MRI imaging within 2 years prior to Screen,
  • •iv. Evidence of cirrhosis by ultrasound, CT, or MRI imaging prior to randomization (for patients who are considered high-risk for liver biopsy, due to thrombocytopenia or bleeding diatheses),
  • •v. Evidence of portal hypertension by previous endoscopy demonstrating moderate to severe esophageal varices protruding from esophagal or upper mucosal gastro-intestinal mucosa within 5 years prior to Screening,
  • •vi. Clinical evidence of portal hypertension documented by history of variceal bleeding, spontaneous bacterial peritonitis (SBP), endoscopic evidence of esophagal varices, or hepatic venous pressure gradient > 15 mmHg within 2 years prior to Screen
  • •Detectable serum HBsAg at the Screening visit
  • •Elevated serum ALT level (1.2 – 10 x ULN) at the Screening visit. If Screening ALT < 1.2xULN, re-test should be >1.2 x ULN or patient should have at least one documented ALT >1.2 x ULN in preceding 12 months.
  • •3. Serum HBV DNA level = 5 log10 copies/mL, as determined by the PCR assay at the central study laboratory at Screen.
  • •4. Patient is ambulatory.
  • •5. Patient is willing and able to comply with the study drug regimen and all other study requirements.
  • •6. The patient is willing and able to provide written informed consent to participate in the study.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1. Patient is pregnant or breastfeeding. Women of childbearing potential must have a
  • •negative serum beta-human chorionic gonadotropin (ß-HCG) at Screening.
  • •2. Patient is of childbearing potential (men and women) and unwilling to use double barrier method of contraception.
  • •3. Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV.
  • •4. Patient previously received more than 8 weeks of continuous lamivudine or
  • •emtricitabine (FTC) treatment or more than 12 total weeks of lamivudine or
  • •emtricitabine (FTC) treatment. If the patient previously received lamivudine or
  • •emtricitabine (FTC) treatment, they must be off treatment for 8 weeks prior to the
  • •Screening visit. A patient who is currently on lamivudine treatment should not be
  • •discontinued from current treatment solely for the purpose of screening for this study.
  • •Previous exposure to adefovir or other PMEA analogs (tenofovir, MCC-478), lobucavir,
  • •entecavir, L-FMAU, L-Fd4C, or other investigational anti-HBV nucleosides/nucleotides
  • •is allowed, but such antiviral treatment must have been discontinued at least 6 months prior to Screening.
  • •5. Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before Screening for this study. Precluded therapies include, but are not limited to, interferon agents (alpha-, beta- or gamma-interferons), thymosin, IL-12, or other putative systemic immunomodulators.
  • •6. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir
  • •7. Patient is currently intubated or has an endotracheal tube for any reason, or requires chronic supplemental oxygen for any reason.
  • •8. Patient has grade 3 or 4 encephalopathy as defined in Appendix 1 of the protocol.
  • •9. Patient has history of acute variceal bleeding or SBP or bacterial sepsis within 8 weeks prior to Screening.
  • •10. Patient has evidence of renal insufficiency defined as patient requires dialysis or has an estimated creatinine clearance, below 70 mL/min, as estimated by the Cockcroft-Gault formula:
  • •11. Patient has a history of hepatocellular carcinoma (HCC) or findings suggestive of
  • •possible HCC.
  • •12. Patient has one or more additional known primary or secondary causes of liver disease.
  • •13. Patient has a history of clinically-evident pancreatitis.
  • •14. Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.
  • •15. Patient has a medical condition that requires frequent or prolonged use of systemic corticosteroids
  • •16. Patient has been on warfarin or other anticoagulants within 30 days prior to Screening or if expected use during the present study.
  • •17. Patient has any other concurrent medical or social condition likely to preclude
  • •compliance with the schedule of evaluations in the protocol, or likely to confound the
  • •efficacy or safety observations of the study, or has other medical or social circumstances likely to interfere with the schedule of evaluations.
  • •18. Patient is enrolled or plans to enroll in another clinical trial of an investigational agent while participating in this study.
  • •19. Patient has any of the following laboratory values at Screening:
  • •Hemoglobin < 9 g/dL for men or < 8 g/dL for women (< 90 g/L for men or < 80 g/L for women)
  • •Total WBC < 1,500/ mm3 (< 1.5 x 109/L)
  • •Absolute neutrophil count (ANC) < 1,000/mm3 (< 1.0x109/L)
  • •Platelet count < 30,000/mm3 (< 30 x 109/L)

研究者

相似试验

进行中（未招募）
1 期
A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of CirrhosisDecompensated Chronic Hepatitis B and Evidence of Cirrhosis
EUCTR2004-000443-17-ESIdenix Pharmaceuticals, Inc.
进行中（未招募）
1 期
A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Continued Lamivudine Treatment in Adults with Compensated Chronic Hepatitis B Who are Currently Receiving Lamivudine Treatmentchronic hepatitis B
EUCTR2004-003754-26-ESIdenix Pharmaceuticals, Inc.230
进行中（未招募）
不适用
A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Continued Lamivudine Treatment in Adults with Compensated Chronic Hepatitis B Who are Currently Receiving Lamivudine Treatmentchronic hepatitis B
EUCTR2004-003754-26-GBIdenix Pharmaceuticals, Inc.230
尚未招募
4 期
Clinical study to evaluate a polyherbal product in individuals with compromised alertness, energy, concentration, and behavioral integrity due to suboptimal Sleep Quality.
CTRI/2022/09/045604Amway Global Services India Pvt Ltd
已完成
不适用
.A.-N30N30
PER-002-96ABORATORIOS BAGO DEL PERU S.A.,